Jurriaan Brouwer-Visser
Overview
Explore the profile of Jurriaan Brouwer-Visser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Topp M, Matasar M, Allan J, Ansell S, Barnes J, Arnason J, et al.
Blood
. 2025 Jan;
PMID: 39786390
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) progressing after chimeric antigen receptor T-cell therapy (CAR T) have dismal outcomes. The prespecified post-CAR T expansion cohort of the ELM-1...
2.
Zhu M, Madia P, Crawford A, Brouwer-Visser J, Krueger P, Haber L, et al.
Clin Transl Sci
. 2024 Dec;
17(12):e70082.
PMID: 39652449
Ubamatamab, a Mucin 16 (MUC16) × cluster of differentiation 3 (CD3) bispecific antibody that promotes T-cell-mediated cytotoxicity of MUC16-expressing cells, is being investigated for the treatment of ovarian cancer. Intravenous...
3.
Brouwer-Visser J, Fiaschi N, Deering R, Cygan K, Scott D, Jeong S, et al.
J Immunother Cancer
. 2024 Mar;
12(3).
PMID: 38519055
Background: Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) have a significant need for effective treatment options. Odronextamab is an Fc-silenced, human, CD20×CD3 bispecific antibody that targets CD20-expressing cells via...
4.
Wei J, Montalvo-Ortiz W, Yu L, Krasco A, Olson K, Rizvi S, et al.
Sci Transl Med
. 2022 Nov;
14(670):eabn1082.
PMID: 36350988
Although many patients with diffuse large B cell lymphoma (DLBCL) may achieve a complete response to frontline chemoimmunotherapy, patients with relapsed/refractory disease typically have poor outcomes. Odronextamab, a CD20xCD3 bispecific...
5.
Weinstock M, Elavalakanar P, Bright S, Ambati S, Brouwer-Visser J, Pourpe S, et al.
Br J Haematol
. 2022 Jul;
199(3):366-370.
PMID: 35892294
Outcomes remain poor for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). While chimeric antigen receptor (CAR) T-cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail...
6.
Irvin S, DOrvilliers A, Bloch N, Boccio K, Pennucci J, Brouwer-Visser J, et al.
AAPS J
. 2022 Jun;
24(4):76.
PMID: 35725847
A cell-based assay was developed to detect neutralizing anti-drug antibodies (NAbs) against odronextamab, a CD20xCD3 bispecific monoclonal antibody (mAb) under investigation for treatment of CD20+ B cell malignancies. In this...
7.
Das Thakur M, Franz C, Brennan L, Brouwer-Visser J, Tam R, Korski K, et al.
Eur J Cancer
. 2022 Jun;
170:179-193.
PMID: 35660252
Background: The clinical development of immune checkpoint-targeted immunotherapies has been disappointing so far in paediatric solid tumours. However, as opposed to adults, very little is known about the immune contexture...
8.
Brennan L, Brouwer-Visser J, Nuesch E, Karpova M, Heller A, Gaire F, et al.
Front Immunol
. 2022 May;
13:760763.
PMID: 35558070
Background: In early stage clinical trials, changes to levels of tumor infiltrating lymphocytes (TILs) in the tumor microenvironment (TME) are critical biomarkers of the mechanism of action of novel immunotherapies....
9.
Dickinson M, Briones J, Herrera A, Gonzalez-Barca E, Ghosh N, Cordoba R, et al.
Blood Adv
. 2021 Sep;
5(22):4762-4770.
PMID: 34581757
Bromodomain and extraterminal (BET) proteins are transcriptional activators for multiple oncogenic processes in diffuse large B-cell lymphoma (DLBCL), including MYC, BCL2, E2F, and toll-like receptor signaling. We report results of...
10.
Mackay A, Burford A, Molinari V, Jones D, Izquierdo E, Brouwer-Visser J, et al.
Cancer Cell
. 2018 May;
33(5):829-842.e5.
PMID: 29763623
The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages...